Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial entities : Regeneron pharmaceuticals, inc. save search
Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept
Published: 2024-02-14 (Crawled : 12:00) - globenewswire.com
REGN | News | $908.42 0.92% 130K
|
Health Technology
|
| O: 0.28%
H: 0.93%
C: 0.5%
OPT | News | $3.38 1.8K
|
Health Technology
|
| O: 0.0%
H: 4.76%
C: -0.85%
first trial
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
Published: 2023-12-10 (Crawled : 20:20) - globenewswire.com
SNY | News | $47.85 1.49% 920K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $908.42 0.92% 130K
|
Health Technology
| Email alert
Add to watchlist
trial potential
EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA
Published: 2023-10-05 (Crawled : 13:30) - globenewswire.com
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
REGN | News | $908.42 0.92% 130K
|
Health Technology
|
| O: 0.0%
H: 2.04%
C: 1.98%
eylea macular trial injection results
Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration
Published: 2023-08-10 (Crawled : 11:00) - globenewswire.com
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: 1.52%
H: 1.05%
C: 0.47%
REGN | News | $908.42 0.92% 130K
|
Health Technology
|
| O: 0.4%
H: 1.32%
C: 0.51%
macular trial results
Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS
Published: 2023-07-29 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.85 1.49% 920K
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $908.42 0.92% 130K
|
Health Technology
| Email alert
Add to watchlist
macular trial results diabetic
Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema
Published: 2023-06-27 (Crawled : 18:00) - globenewswire.com
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: 0.75%
H: 0.0%
C: 0.0%
REGN | News | $908.42 0.92% 130K
|
Health Technology
|
| O: -1.1%
H: 0.26%
C: -1.16%
macular trial results diabetic
Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma
Published: 2023-05-25 (Crawled : 21:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 0.5%
H: 1.67%
C: 1.67%
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: -0.21%
H: 0.0%
C: 0.0%
REGN | News | $908.42 0.92% 130K
|
Health Technology
|
| O: 0.0%
H: 0.24%
C: 0.01%
trial
Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices (AEMPS) to Initiate Clinical Development of Lead Gene Therapy Candidate DB-OTO
Published: 2023-05-12 (Crawled : 11:00) - globenewswire.com
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: 0.84%
H: 6.94%
C: 0.28%
REGN | News | $908.42 0.92% 130K
|
Health Technology
|
| O: 0.48%
H: 0.36%
C: -0.64%
candidate approval medical application trial therapeutics therapy
Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
Published: 2023-03-23 (Crawled : 08:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 5.54%
H: 0.96%
C: 0.96%
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: 6.53%
H: 0.56%
C: -0.54%
REGN | News | $908.42 0.92% 130K
|
Health Technology
|
| O: 7.34%
H: 0.77%
C: -0.53%
dupixent copd trial potential
Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO
Published: 2023-01-24 (Crawled : 13:20) - biospace.com/
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: -0.15%
H: 18.49%
C: 15.32%
REGN | News | $908.42 0.92% 130K
|
Health Technology
|
| O: 0.15%
H: 0.18%
C: -0.48%
candidate application trial approval therapeutics therapy
Odronextamab (CD20xCD3) Demonstrates High and Durable Complete Response Rate among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 Trial
Published: 2022-12-12 (Crawled : 23:00) - prnewswire.com
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: 1.46%
H: 0.0%
C: 0.0%
REGN | News | $908.42 0.92% 130K
|
Health Technology
|
| O: 0.89%
H: 0.65%
C: -0.21%
cd20 trial response
Press Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis
Published: 2022-07-14 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -1.46%
H: 0.09%
C: 0.09%
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
REGN | News | $908.42 0.92% 130K
|
Health Technology
|
| O: -1.0%
H: 1.64%
C: 0.48%
dupixent children trial positive results
Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Regeneron Pharmaceuticals, Inc. and Sanofi announced that a Phase 3 trial asses...
Published: 2022-07-14 (Crawled : 07:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -1.46%
H: 0.09%
C: 0.09%
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
REGN | News | $908.42 0.92% 130K
|
Health Technology
|
| O: -1.0%
H: 1.64%
C: 0.48%
dupixent children trial positive results sanofi phase 3
Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis
Published: 2022-07-14 (Crawled : 06:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -1.46%
H: 0.09%
C: 0.09%
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
REGN | News | $908.42 0.92% 130K
|
Health Technology
|
| O: -1.0%
H: 1.64%
C: 0.48%
dupixent children trial positive results phase 3
Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol
Published: 2022-05-21 (Crawled : 12:20) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.85 1.49% 920K
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $908.42 0.92% 130K
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
evkeeza children cholesterol trial phase 3 rare
SpringWorks Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Regeneron to Evaluate Nirogacestat in Combination with REGN5458 in Patients with Relapsed or Refractory Multiple Myeloma
Published: 2022-04-19 (Crawled : 11:00) - globenewswire.com
SWTX | $45.28 5.57% 550K
|
Health Technology
|
| O: -8.22%
H: 4.35%
C: 3.58%
REGN | News | $908.42 0.92% 130K
|
Health Technology
|
| O: -0.18%
H: 0.22%
C: -1.1%
regn5458 collaboration trial therapeutics
Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis
Published: 2022-01-19 (Crawled : 07:00) - globenewswire.com
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: -1.41%
H: 0.0%
C: 0.0%
REGN | News | $908.42 0.92% 130K
|
Health Technology
|
| O: 1.84%
H: 1.79%
C: 0.18%
dupixent trial positive phase 3
Second Dupixent® (dupilumab) Phase 3 Eosinophilic Esophagitis Trial to Demonstrate Significant Disease Improvements, Underscoring Role of Type 2 Inflammation in This Complex Disease
Published: 2021-10-25 (Crawled : 05:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 1.02%
H: 0.0%
C: 0.0%
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: 0.89%
H: 0.26%
C: -0.12%
REGN | News | $908.42 0.92% 130K
|
Health Technology
|
| O: 0.38%
H: 0.88%
C: 0.44%
disease phase 3 trial dupixent
Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease
Published: 2021-10-22 (Crawled : 09:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: -0.41%
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
REGN | News | $908.42 0.92% 130K
|
Health Technology
|
| O: 0.37%
H: 0.0%
C: 0.0%
disease phase 3 skin trial dupixent
New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19
Published: 2021-09-29 (Crawled : 21:00) - prnewswire.com
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: -0.02%
H: 0.2%
C: -0.31%
REGN | News | $908.42 0.92% 130K
|
Health Technology
|
| O: 0.17%
H: 0.96%
C: -0.42%
covid positive results casirivimab phase 3 trial trial results
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.64 166.67% 18M
|
AGBA | $2.61 108.8% 41M
|
Finance
CZOO | $9.32 86.77% 18M
|
EDBL | News | $6.7 78.19% 1.7M
|
OPRT | News | $3.37 49.78% 8.9M
|
Finance
MTC | $2.14 37.18% 4.9M
|
Technology Services
VNRX | $0.8 33.33% 2.9M
|
Health Technology
MLEC | $1.79 27.86% 2.6M
|
n/a
PALI | $6.29 27.59% 22M
|
Manufacturing
MCRB | $0.7902 26.51% 6.9M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.